Objective: Diagnostic frequency ratios such as the atypia of undetermined significance (AUS):malignant ratio are touted to be useful for laboratory precision benchmarking. We therefore sought to examine their reproducibility and usefulness at a tertiary hospital. Methods: We reviewed thyroid fine-needle aspirates (FNA) submitted to our institution from outside laboratories and evaluated the ability of diagnostic frequency ratios to capture the complexity of The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). Specifically, we evaluated the ability of the AUS:malignant ratio to describe the frequencies of the other TBSRTC diagnoses. Results: A total of 2,784 cases from 19 laboratories were included. The use of the AUS category varied the most. There was insufficient reflection of the non-AUS nonmalignant TBSRTC diagnostic frequencies in our analysis, and these results do not appear to arise from observer variability in the outside laboratories. Conclusion: Diagnostic frequency ratios are not reproducible in our experience and fail to describe the other TBSRTC categories. As such, they are unlikely to prove sufficient for benchmarking laboratory precision with TBSRTC.

Keywords:
Thyroid cytopathology, Fine-needle aspiration, Quality assurance, Atypia of undetermined significance, The Bethesda System for Reporting Thyroid Cytopathology
1.
Gharib H: Fine-needle aspiration biopsy of thyroid nodules: advantages, limitations, and effect. Mayo Clin Proc 1994;69:44-49.
2.
Cibas ES, Alexander EK, Benson CB, de Agustin PP, Doherty GM, Faquin WC, Middleton WD, Miller T, Raab SS, White ML, Mandel SJ: Indications for thyroid FNA and pre-FNA requirements: a synopsis of the national cancer institute thyroid fine-needle aspiration state of the science conference. Diagn Cytopathol 2008;36:390-399.
3.
Ali SZ: Thyroid cytopathology: Bethesda and beyond. Acta Cytol 2011;55:4-12.
4.
Olson MT, Boonyaarunnate T, Altinboga AA, Ali SZ: ‘Suspicious for papillary thyroid carcinoma' before and after the Bethesda System for Reporting Thyroid Cytopathology: impact of standardized terminology. Acta Cytol 2014;58:15-22.
5.
Boonyaarunnate T, Olson MT, Ali SZ: ‘Suspicious for a follicular neoplasm' before and after the Bethesda System for Reporting Thyroid Cytopathology: IMPACT of standardized terminology. Acta Cytol 2013;57:455-463.
6.
Krane JF, Vanderlaan PA, Faquin WC, Renshaw AA: The atypia of undetermined significance/follicular lesion of undetermined significance:malignant ratio: a proposed performance measure for reporting in the Bethesda System for thyroid cytopathology. Cancer Cytopathol 2012;120:111-116.
7.
Layfield LJ, Morton MJ, Cramer HM, Hirschowitz S: Implications of the proposed thyroid fine-needle aspiration category of ‘follicular lesion of undetermined significance': a five-year multi-institutional analysis. Diagn Cytopathol 2009;37:710-714.
8.
Nayar R, Ivanovic M: The indeterminate thyroid fine-needle aspiration: experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Cancer 2009;117:195-202.
9.
Shi Y, Ding X, Klein M, Sugrue C, Matano S, Edelman M, Wasserman P: Thyroid fine-needle aspiration with atypia of undetermined significance: a necessary or optional category? Cancer 2009;117:298-304.
10.
Olson MT, Clark DP, Erozan YS, Ali SZ: Spectrum of risk of malignancy in subcategories of ‘atypia of undetermined significance'. Acta Cytol 2011;55:518-525.
11.
Kim SK, Hwang TS, Yoo YB, Han HS, Kim DL, Song KH, Lim SD, Kim WS, Paik NS: Surgical results of thyroid nodules according to a management guideline based on the BRAF(v600e) mutation status. J Clin Endocrinol Metab 2011;96:658-664.
12.
Davey DD, Woodhouse S, Styer P, Stastny J, Mody D: Atypical epithelial cells and specimen adequacy: current laboratory practices of participants in the College of American Pathologists interlaboratory comparison program in cervicovaginal cytology. Arch Pathol Lab Med 2000;124:203-211.
13.
Juskevicius R, Zou KH, Cibas ES: An analysis of factors that influence the ASCUS/SIL ratio of pathologists. Am J Clin Pathol 2001;116:331-335.
14.
Nascimento AF, Cibas ES: The ASC/SIL ratio for cytopathologists as a quality control measure: a follow-up study. Am J Clin Pathol 2007;128:653-656.
15.
Olson MT, Breaud A, Harlan R, Emezienna N, Schools S, Yergey AL, Clarke W: Alternative calibration strategies for the clinical laboratory: application to nortriptyline therapeutic drug monitoring. Clin Chem 2013;59:920-927.
16.
Olson MT, Kickler TS, Lawson JA, McLean RC, Jani J, FitzGerald GA, Rade JJ: Effect of assay specificity on the association of urine 11-dehydro thromboxane B2 determination with cardiovascular risk. J Thromb Haemost 2012;10:2462-2469.
17.
Kleiman DA, Sporn MJ, Beninato T, Crowley MJ, Nguyen A, Uccelli A, Scognamiglio T, Zarnegar R, Fahey TJ 3rd: Preoperative BRAF(v600e) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules: a prospective case series of 960 patients. Cancer 2013;119:1495-1502.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.